Boehringer Ingelheim GMBH is becoming more active in the competitive oncology business development marketplace as the firm tries to broaden its footprint in cancer.
Boehringer Increasingly Looking Outside For Oncology Growth
The private company has stressed home-grown candidates, but it's making more external plays as it builds oncology as one of the pillars of the business.
More from Anticancer
• By
Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.
• By
The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.
• By
Adstiladrin sales hit €70m in first full year on the market
• By
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.
More from Therapy Areas
• By
Adstiladrin sales hit €70m in first full year on the market
• By
ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.
• By
The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.